AAV

WuXi ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services for Global Customers

Monday, October 18, 2021 - 4:05am

WuXi ATU is a leading Contract, Testing, Development and Manufacturing Organization (CTDMO) headquartered in Philadelphia.

Key Points: 
  • WuXi ATU is a leading Contract, Testing, Development and Manufacturing Organization (CTDMO) headquartered in Philadelphia.
  • As its fourth manufacturing site worldwide, the new facility will supplement WuXi ATU's global footprint and will further join with other sites in the United States, United Kingdom and China to enable global customers with enhanced capacity and efficient services.
  • The Lin-gang facilityoffers integrated development, manufacturing, and testing services for viral vectors and cell therapies.
  • As the wholly owned subsidiary of WuXi AppTec, WuXi ATU is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies.

Chinese Premier Visited EHang Exhibition Booth at the China Import and Export Fair

Friday, October 15, 2021 - 2:53pm

GUANGZHOU, China, Oct. 15, 2021 (GLOBE NEWSWIRE) -- The 130th China Import and Export Fair ("Canton Fair") officially kicked off on October 14th in Guangzhou, Guangdong Province, China.

Key Points: 
  • GUANGZHOU, China, Oct. 15, 2021 (GLOBE NEWSWIRE) -- The 130th China Import and Export Fair ("Canton Fair") officially kicked off on October 14th in Guangzhou, Guangdong Province, China.
  • Chinese Premier Li Keqiang was in attendance at the opening ceremony and visited the exhibition booth of EHang Holdings Limited (Nasdaq: EH) (EHang or the Company), the worlds leading autonomous aerial vehicle (AAV) technology platform company.
  • The EHang AAV products have achieved notably satisfactory results in the field of smart transportation.
  • Chinese Premier Li urged the Company to ensure product safety, create high-quality products, and continuously improve competitiveness in the international market.

AGTC Announces Two Key Leadership Team Appointments

Thursday, October 14, 2021 - 10:00pm

Dr. Schneiders wealth of ophthalmology experience and impressive accomplishments bring valuable expertise to AGTCs leadership team.

Key Points: 
  • Dr. Schneiders wealth of ophthalmology experience and impressive accomplishments bring valuable expertise to AGTCs leadership team.
  • An ophthalmologist by training, her expertise in developing high performing ophthalmic therapeutic teams and building strong cross-functional programs will further strengthen AGTCs leadership in advancing their clinical stage assets.
  • AGTC is a leader in the field and working to meet important unmet medical needs in the ophthalmology community.
  • Additionally, AGTC is pleased to announce the appointment of Sarah C. DiSalvatore, M.P.H., as Vice President of Clinical Operations.

PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility

Thursday, October 14, 2021 - 1:30pm

SOUTH PLAINFIELD, N.J., Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc.(NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene therapy manufacturing facility in Hopewell, N.J. today at 4 p.m.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc.(NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene therapy manufacturing facility in Hopewell, N.J. today at 4 p.m.
  • "We are committed to being an innovation-based company that brings the best therapies to patients with rare diseases," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics.
  • We have built our capabilities to both perform gene therapy research and to manufacture these biological products.
  • The Hopewell gene therapy manufacturing center complements PTC's existing operations at the Company's global headquarters in South Plainfield, N.J. and brings the total number of New Jersey-based employees to 625.

Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses

Wednesday, October 13, 2021 - 12:30pm

NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021.

Key Points: 
  • NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021.
  • The Companys development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need.
  • Abeonas novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
  • Abeonas fully integrated gene and cell therapy cGMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL study and is capable of clinical and planned commercial production of AAV-based gene therapies.

Selecta Biosciences to Present New Data for the ImmTOR™ platform at the ESGCT 28th Annual Congress

Wednesday, October 13, 2021 - 1:00pm

The posters will become available online on Tuesday 19th October 2021 at 08:00am CEST.

Key Points: 
  • The posters will become available online on Tuesday 19th October 2021 at 08:00am CEST.
  • Through co-administration of ImmTOR with AAV-mediated gene therapies, we have the opportunity to unlock the full potential of these life-altering treatments for patients in need.
  • Selecta Biosciences Inc.(NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses.
  • The Company specifically disclaims any intention to update any forward-looking statements included in this press release.

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Wednesday, October 13, 2021 - 12:01pm

and PARIS, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, and SparingVision, a genomic medicine company developing vision saving treatments for ocular diseases, today announced a strategic collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases.

Key Points: 
  • and PARIS, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, and SparingVision, a genomic medicine company developing vision saving treatments for ocular diseases, today announced a strategic collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases.
  • SparingVision will lead and fund the preclinical and clinical development for the genome editing product candidates pursued under the collaboration.
  • Intellia will also maintain the ability to leverage technology advances established under this collaboration for any targets outside the partnership.
  • Please find a link to join this webcast here: https://us02web.zoom.us/j/83682810928
    Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology.

LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies Announce Collaboration to Support Development and Manufacturing of Gene Therapies for Genetic Diseases

Wednesday, October 13, 2021 - 12:30pm

Were confident that FUJIFILM Diosynth Biotechnologies industry leading technology expertise and experience in gene therapy manufacturing will help position LEXEO for long-term success as we advance programs from early to late clinical studies, said Paul McCormac, Senior Vice President, Technical Operations of LEXEO Therapeutics.

Key Points: 
  • Were confident that FUJIFILM Diosynth Biotechnologies industry leading technology expertise and experience in gene therapy manufacturing will help position LEXEO for long-term success as we advance programs from early to late clinical studies, said Paul McCormac, Senior Vice President, Technical Operations of LEXEO Therapeutics.
  • LEXEO Therapeutics is a New York City-based fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic cardiovascular conditions and genetic conditions of the central nervous system (CNS).
  • LEXEOs current pipeline consists of adeno-associated virus (AAV)- mediated gene therapies in rare cardiac diseases, CLN2 Batten disease, and APOE4-associated Alzheimers disease.
  • FUJIFILM Diosynth Biotechnologies is an industry-leading biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerd, Denmark.

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Wednesday, October 13, 2021 - 12:00pm

As part of this collaboration, Intellia will grant SparingVision exclusive rights to Intellias proprietary in vivo CRISPR/Cas9-based genome editing technology for up to three ocular targets addressing diseases with significant unmet medical need.

Key Points: 
  • As part of this collaboration, Intellia will grant SparingVision exclusive rights to Intellias proprietary in vivo CRISPR/Cas9-based genome editing technology for up to three ocular targets addressing diseases with significant unmet medical need.
  • SparingVision will lead and fund the preclinical and clinical development for the genome editing product candidates pursued under the collaboration.
  • Intellia will also maintain the ability to leverage technology advances established under this collaboration for any targets outside the partnership.
  • Please find a link to join this webcast here: https://us02web.zoom.us/j/83682810928
    Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology.

Poseida Therapeutics Announces Leadership Appointments

Wednesday, October 13, 2021 - 1:00pm

SAN DIEGO, Oct. 13, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced appointments to new roles on its executive leadership team.

Key Points: 
  • SAN DIEGO, Oct. 13, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced appointments to new roles on its executive leadership team.
  • She holds a Bachelor of Accountancy degree from the University of San Diego and is a Certified Public Accountant.
  • Ms. Martin most recently served as Chief Human Resources Officer upon joining Poseida in 2019.
  • Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.